Member Info for jollyspeculator

looks G8 ...(I'm always bemused by seeming lack of interest in a play like this at LSE ...but what we lack in numbers, the 3 of us more than make up in quality ...in my Jolly humble opinion lol)

I'm on yr case...saw that lol... ...best of luck... ...looks a triffle pricey over there... but wtfdik??

given massive premium to NAV ...simplesz imv ...aaoo/dyor all

i called this hopelessly wrong @4p lol... ...so not at all sure... ...if the ceo didn't own a decent slug, I'd be v worried about a placement at a low sp ...so I am balanced between modest worry about placement/dilution and interest in potential

...lining up sub 0.4p for Jolly further rebuy of earlier topslice

...this is like a cork about to pop out of the champers bottle imv

tedious...but effective?...a least sometimes lol ...this is currently an unprofitable business (judging by last rns)... ...yet to show the robustness of its business model imv ...I would look for decent margin for safety to justify investment/punt

again...decent support here at earlier placement price of 20p ...the upside potential is clearly huge (as long as they get paid lol) ...all opinion only of course

Said Symphony's CEO, Michael Laurier, who was present throughout the event "There was exceptional demand for d2w - our well-established oxo-biodegradable masterbatch, as the best and least expensive option for biodegradation of plastics. It turns plastic into a biodegradable material at the end of its useful life. Great interest was also shown in our new d2p range of anti-fungal and anti-microbial plastics, and our d2t range of anti-counterfeiting technologies." "More than 600 requests for further information were recorded by Symphony's staff, from end users, processors and raw material producers."

but still early days

u holding on?

...looks like a potential LT winner, doesn't it? ...Jolly kicking myself that I didn't buy into rise...excellent 2* money but on piddly amount (good illustration of why IRRs are useless...it's the NPV that matters, stupid lol) ...expect to be topping up on dips

to the incumbent technologies still being used around the world." says CEO ...well, all sounds Jolly good

Peer-reviewed published article supporting Tristel's technology and products Tristel plc (AIM: TSTL), the manufacturer of infection prevention, contamination control and hygiene products, announces the publication of an article in a peer-reviewed journal that describes the benefits of Tristel products. The study is titled "A randomised single-blind comparison of the effectiveness of the high-level disinfectants Tristel Fuse (chlorine dioxide) and Cidex OPA (ortho-phthaldehyde) for use with flexible cystoscopes". It has been published in The British Journal of Urology International (on line 10.1111 BJU 12208) and will be published within the Urological Society of Australia and New Zealand (special issue volume 112). The article compares the effectiveness, safety and cost of Tristel's chlorine dioxide Fuse chemistry with Cidex OPA (Johnson & Johnson, USA), in an automated endoscope reprocessor (Medivators Inc, USA) for high level disinfection of flexible cystoscopes. Tristel Fuse, which was used within the Company's Stella decontamination system, was found to be as effective, more economic and easier for the nursing staff to use than the American products with which it was compared. Tristel CEO, Paul Swinney, commented: "This study was initiated in 2009 by the Department of Urology, Tauranga Hospital, New Zealand, and the initial results were reported at the Societe Internationale d'Urologie congress, Shanghai, 2011. "This is the first published study that compares our Tristel Fuse and Stella system with one of the world's leading combinations of disinfectant and endoscope washing machine. It demonstrates that our chlorine dioxide technology is just as safe and effective as the world's most widely used medical instrument disinfectant, whilst producing cost savings for hospitals. "This study joins the growing body of published scientific evidence demonstrating that Tristel products are superior to the incumbent technologies still being used around the world."

explanation of difference between yr figures and adjusted EBIT "[Note] 4 [of final results]. NON RECURRING ITEMS Following a review and restructure of the business during the year headcount has fallen by 15%; the operation in China has been restructured to cease the drain on cash; and the IP portfolio in the Balance Sheet has been reviewed with the result that certain assets relating to legacy products have been impaired. These 'root and branch review' activities have culminated in a non-cash exceptional charge of £2.2 million. During the prior year the Group carried out a re-structuring of its engineering function resulting in a provision against slow moving inventory held at the year end and staff redundancy costs, which in aggregate amounted to £119,583. In the current year further provisions have been made against slow moving inventory totaling £199,000.

H2 adjusted pre-tax profit of £1.1m from H1 adjusted pre-tax loss of £0.6m, giving adjusted* pre-tax profit £0.5m for the year (2012: £0.7m) ...I am broadly happy with adjustments ...so 2H EBIT of £1.1m ...so run rate (annualised) EBIT of 2*£1.1m ....so EV/EBIT currently only c6 ..soooooooooooooo still Jolly cheap imv ....if turnaround success, why not EBIT of £3m & EV/EBIT of c10 to reflect excellent growth prospects (see post above for peer review of tech) ...so sp of 70p+ anyone lol??? ..aaoo/dyor/no advice intended

OMG

OMG

not heard that one...yuck

not shabby